• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Context Therapeutics Inc (NQ: CNTX )

    2.545 -0.065 (-2.49%)
    Streaming Delayed Price Updated: 2:22 PM EDT, Aug 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Context Therapeutics Inc

    < Previous 1 2 3 4 5 Next >
    Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
    From Context Therapeutics Inc.
    Via GlobeNewswire
    Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
    From Context Therapeutics Inc.
    Via GlobeNewswire
    Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
    From Context Therapeutics Inc.
    Via GlobeNewswire
    Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight
    If you believe in chasing the winners higher, here are three hypergrowth stocks that may provide Nvidia-like gains. 
    Via InvestorPlace
    Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update
    --News Direct-- 
    Via News Direct
    The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
    Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them. 
    Via InvestorPlace
    CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024
    CNTX stock results show that Context Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
    From Context Therapeutics Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
    From Context Therapeutics Inc.
    Via GlobeNewswire
    Context Therapeutics Announces $100 Million Private Placement
    From Context Therapeutics Inc.
    Via GlobeNewswire
    Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
    Important Regulatory Milestone Supports Next Phase of CTIM-76 Development 
    From Context Therapeutics Inc.
    Via GlobeNewswire
    CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023
    CNTX stock results show that Context Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Context Therapeutics Reports Full Year 2023 Operating and Financial Results
    From Context Therapeutics Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7% to... 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday
    U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday. Here are some other big stocks recording gains in today’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
    From Context Therapeutics Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
    From Context Therapeutics Inc.
    Via GlobeNewswire
    10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket
    Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not... 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Pre-market stock movers are worth checking out on Monday as we start off the week with all the latest news this morning! 
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
    From Context Therapeutics Inc.
    Via GlobeNewswire
    Benzinga's Top Ratings Upgrades, Downgrades For September 11, 2023
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.